Skip to main content
ReproCELL Incorporated logo

ReproCELL Incorporated — Investor Relations & Filings

Ticker · 4978 ISIN · JP3974770004 LEI · 529900NM7KR32GGRSU46 T Professional, scientific and technical activities
Open in API
Filings indexed 62 across all filing types
Latest filing 2022-06-29 Annual Report
Country JP Japan
Listing T 4978

About ReproCELL Incorporated

https://www.reprocell.com/

ReproCELL Incorporated is a global company providing solutions for preclinical and clinical research, with a primary focus on stem cell technology, drug discovery, and regenerative medicine. The company's portfolio includes a wide range of products such as induced pluripotent stem cells (iPSCs), differentiated cells, 3D cell culture models, and specialized reagents like RNA-based reprogramming kits that avoid genomic integration. ReproCELL also offers extensive contract research services, including human tissue assays for evaluating drug efficacy and safety. A key area of expertise is the GMP-compliant manufacturing of clinical-grade iPSCs and iPSC-derived mesenchymal stem cells (iMSCs), supporting the development of advanced cell therapies. The company's tools and services are designed to help academic and commercial scientists accelerate the translation of research into clinical applications.

Recent filings

Filing Released Lang Actions
有価証券報告書－第20期(令和3年4月1日－令和4年3月31日)
Annual Report Classification · 100% confidence The document is a Japanese '有価証券報告書' (Yuuka Shouken Houkokusho), which is the standard Japanese equivalent of an Annual Report (10-K). It contains the official filing header, the fiscal year period (2021-04-01 to 2022-03-31), and detailed financial data structures (XBRL tags, consolidated financial indicators). It is not an announcement or a certification, but the full annual report itself. FY 2022
2022-06-29 Japanese
四半期報告書－第20期第3四半期(令和3年10月1日－令和3年12月31日)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for ReproCELL Incorporated, covering the third quarter of the 20th fiscal period (October 1, 2021, to December 31, 2021). It contains detailed financial statements, management analysis (MDA), and corporate information as required by the Financial Instruments and Exchange Act of Japan. Since it is a comprehensive quarterly financial report containing actual financial data and analysis, it is classified as an Interim/Quarterly Report (IR). Q3 2022
2022-02-10 Japanese
四半期報告書－第20期第2四半期(令和3年7月1日－令和3年9月30日)
Interim / Quarterly Report Classification · 100% confidence The document is a '第２四半期報告書' (Quarterly Report) for ReproCELL Incorporated, covering the period from July 1, 2021, to September 30, 2021. It contains detailed financial statements, management analysis (MDA), and business status updates, which are characteristic of an Interim/Quarterly Report (IR). It is not an announcement of a report, but the report itself. Q2 2021
2021-11-12 Japanese
四半期報告書－第20期第1四半期(令和3年4月1日－令和3年6月30日)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for ReproCELL Incorporated, covering the first quarter of the 20th fiscal year (April 1, 2021, to June 30, 2021). It contains detailed financial statements, management analysis (MDA), and business status updates, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2021
2021-08-13 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is titled '確認書' (Confirmation Letter) and explicitly cites '金融商品取引法第24条の４の２第１項' (Article 24-4-2, Paragraph 1 of the Financial Instruments and Exchange Act). It serves as an officer certification regarding the accuracy of the company's Annual Securities Report (有価証券報告書). According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations should be classified as Regulatory Filings (RNS), even if they reference a specific report type. FY 2021
2021-06-28 Japanese
内部統制報告書－第19期(令和2年4月1日－令和3年3月31日)
Governance Information Classification · 100% confidence The document is an 'Internal Control Report' (内部統制報告書) filed under the Financial Instruments and Exchange Act (金融商品取引法). This type of report details the company's internal control framework, evaluation scope, and results regarding financial reporting. In the context of Japanese regulatory filings, this is a specific governance-related disclosure. Since it does not fit into the standard financial reporting categories like 10-K or IR, and is a formal regulatory filing required by law, it is best classified as a Regulatory Filing (RNS).
2021-06-28 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.